{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T11:32:10Z","timestamp":1762342330678,"version":"3.33.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,6,8]],"date-time":"2024-06-08T00:00:00Z","timestamp":1717804800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,6,8]],"date-time":"2024-06-08T00:00:00Z","timestamp":1717804800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Chin. J. Integr. Med."],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1007\/s11655-024-3809-2","type":"journal-article","created":{"date-parts":[[2024,6,8]],"date-time":"2024-06-08T07:02:10Z","timestamp":1717830130000},"page":"142-152","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Stir-fried Semen Armeniacae Amarum Suppresses Aristolochic Acid I-Induced Nephrotoxicity and DNA Adducts"],"prefix":"10.1007","volume":"31","author":[{"given":"Cheng-xian","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao-he","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin-yu","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Da-ke","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yin-kang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xian-ling","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ping","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-rong","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming","family":"Niu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhao-fang","family":"Bai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,6,8]]},"reference":[{"key":"3809_CR1","doi-asserted-by":"publisher","first-page":"215","DOI":"10.3389\/fphar.2017.00215","volume":"8","author":"J Michl","year":"2017","unstructured":"Michl J, Bello O, Kite GC, Simmonds MSJ, Heinrich M. Medicinally used Asarum species: high-resolution LC\u2013MS analysis of aristolochic acid analogs and in vitro toxicity screening in HK-2 cells. Front Pharmacol 2017;8:215.","journal-title":"Front Pharmacol"},{"key":"3809_CR2","doi-asserted-by":"publisher","first-page":"116568","DOI":"10.1016\/j.jep.2023.116568","volume":"315","author":"J Tian","year":"2023","unstructured":"Tian J, Liu C, Wang L, Xian Z, Zhao Y, Qin S, et al. Study on the difference and correlation between the contents and toxicity of aristolochic acid analogues in Aristolochia plants. J Ethnopharmacol 2023;315:116568.","journal-title":"J Ethnopharmacol"},{"key":"3809_CR3","first-page":"355","volume":"93","author":"T Tomlinson","year":"2020","unstructured":"Tomlinson T, Fernandes A, Grollman AP. Aristolochia herbs and iatrogenic disease: the case of Portland\u2019s powders. Yale J Biol Med 2020;93:355\u2013363.","journal-title":"Yale J Biol Med"},{"key":"3809_CR4","doi-asserted-by":"publisher","first-page":"e4000","DOI":"10.1136\/bmj.e4000","volume":"344","author":"MR G\u00f6kmen","year":"2012","unstructured":"G\u00f6kmen MR, Lord GM. Aristolochic acid nephropathy. BMJ 2012;344:e4000.","journal-title":"BMJ"},{"key":"3809_CR5","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1056\/NEJM200310163491619","volume":"349","author":"LS Gold","year":"2003","unstructured":"Gold LS, Slone TH. Aristolochic acid, an herbal carcinogen, sold on the web after FDA alert. N Engl J Med 2003;349:1576\u20131577.","journal-title":"N Engl J Med"},{"key":"3809_CR6","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1038\/ki.2011.371","volume":"81","author":"B Jelakovi\u0107","year":"2012","unstructured":"Jelakovi\u0107 B, Karanovi\u0107 S, Vukovi\u0107-Lela I, Miller F, Edwards KL, Nikoli\u0107 J, et al. Aristolactam-DNA adducts are a biomarker of environmental exposure to aristolochic acid. Kidney Int 2012;81:559\u2013567.","journal-title":"Kidney Int"},{"key":"3809_CR7","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1038\/s41568-022-00494-x","volume":"22","author":"S Das","year":"2022","unstructured":"Das S, Thakur S, Korenjak M, Sidorenko VS, Chung FFL, Zavadil J. Aristolochic acid-associated cancers: a public health risk in need of global action. Nat Rev Cancer 2022;22:576\u2013591.","journal-title":"Nat Rev Cancer"},{"key":"3809_CR8","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1039\/C9RA08327H","volume":"10","author":"Y Fan","year":"2020","unstructured":"Fan Y, Li Z, Xi J. Recent developments in detoxification techniques for aristolochic acid-containing traditional Chinese medicines. RSC Adv 2020;10:1410\u20131425.","journal-title":"RSC Adv"},{"key":"3809_CR9","doi-asserted-by":"publisher","first-page":"648","DOI":"10.3389\/fphar.2019.00648","volume":"10","author":"J Han","year":"2019","unstructured":"Han J, Xian Z, Zhang Y, Liu J, Liang A. Systematic overview of amristolochic acids: nephrotoxicity, carcinogenicity, and underlying mechanisms. Front Pharmacol 2019;10:648.","journal-title":"Front Pharmacol"},{"key":"3809_CR10","doi-asserted-by":"publisher","first-page":"4277","DOI":"10.1111\/jcmm.17451","volume":"26","author":"R Upadhyay","year":"2022","unstructured":"Upadhyay R, Batuman V. Aristolochic acid I induces proximal tubule injury through ROS\/HMGB1\/mt DNA mediated activation of TLRs. J Cell Mol Med 2022;26:4277\u20134291.","journal-title":"J Cell Mol Med"},{"key":"3809_CR11","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1093\/ndt\/gfr291","volume":"27","author":"L Yang","year":"2012","unstructured":"Yang L, Su T, Li XM, Wang X, Cai SQ, Meng LQ, et al. Aristolochic acid nephropathy: variations in presentation and prognosis. Nephrol Dial Transplant 2012;27:292\u2013298.","journal-title":"Nephrol Dial Transplant"},{"key":"3809_CR12","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.2215\/CJN.11571017","volume":"13","author":"B Yang","year":"2018","unstructured":"Yang B, Xie Y, Guo M, Rosner MH, Yang H, Ronco C. Nephrotoxicity and Chinese herbal medicine. Clin J Am Soc Nephrol 2018;13:1605\u20131611.","journal-title":"Clin J Am Soc Nephrol"},{"key":"3809_CR13","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1002\/ijc.25324","volume":"128","author":"VM Arlt","year":"2011","unstructured":"Arlt VM, Zuo J, Trenz K, Roufosse CA, Lord GM, Nortier JL, et al. Gene expression changes induced by the human carcinogen aristolochic acid I in renal and hepatic tissue of mice. Int J Cancer 2011;128:21\u201332.","journal-title":"Int J Cancer"},{"key":"3809_CR14","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1093\/toxsci\/kfr306","volume":"125","author":"M Stiborov\u00e1","year":"2012","unstructured":"Stiborov\u00e1 M, Levov\u00e1 K, B\u00e1rta F, Shi Z, Frei E, Schmeiser HH, et al. Bioactivation versus detoxification of the urothelial carcinogen aristolochic acid I by human cytochrome P450 1A1 and 1A2. Toxicol Sci 2012;125:345\u2013358.","journal-title":"Toxicol Sci"},{"key":"3809_CR15","doi-asserted-by":"publisher","first-page":"e95978","DOI":"10.1172\/jci.insight.95978","volume":"2","author":"SY Chang","year":"2017","unstructured":"Chang SY, Weber EJ, Sidorenko VS, Chapron A, Yeung CK, Gao C, et al. The human liver-kidney model elucidates the mechanisms of aristolochic acid nephrotoxicity. JCI Insight 2017;2:e95978.","journal-title":"JCI Insight"},{"key":"3809_CR16","series-title":"dissertation","volume-title":"Research of utilising law of Asari Radix et Rhizoma based on relativity of toxicity-efficacy-syndrome","author":"J Li","year":"2011","unstructured":"Li J. Research of utilising law of Asari Radix et Rhizoma based on relativity of toxicity-efficacy-syndrome [dissertation]. Jinan: Shandong University of Traditional Chinese Medicine; 2011."},{"key":"3809_CR17","first-page":"e59843","volume":"149","author":"S Di Cocco","year":"2019","unstructured":"Di Cocco S, Belloni L, Nunn ADG, Salerno D, Piconese S, Levrero M, et al. Inducing and characterizing vesicular steatosis in differentiated HepaRG cells. J Vis Exp 2019;149:e59843.","journal-title":"J Vis Exp"},{"key":"3809_CR18","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.3390\/cells9102288","volume":"9","author":"J Lucifora","year":"2020","unstructured":"Lucifora J, Michelet M, Salvetti A, Durantel D. Fast differentiation of HepaRG cells allowing hepatitis B and delta virus infections. Cells 2020;9:2288.","journal-title":"Cells"},{"key":"3809_CR19","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1248\/bpb.b16-00319","volume":"39","author":"N Nakamichi","year":"2016","unstructured":"Nakamichi N, Ishimoto T, Yamauchi Y, Masuo Y, Kato Y. Screening to identify multidrug resistance-associated protein inhibitors with neuroblastoma-selective cytotoxicity. Biol Pharm Bull 2016;39:1638\u20131645.","journal-title":"Biol Pharm Bull"},{"key":"3809_CR20","doi-asserted-by":"publisher","first-page":"105384","DOI":"10.1016\/j.phrs.2020.105384","volume":"164","author":"H Liu","year":"2021","unstructured":"Liu H, Zhan X, Xu G, Wang Z, Li R, Wang Y, et al. Cryptotanshinone specifically suppresses NLRP3 inflammasome activation and protects against inflammasome-mediated diseases. Pharmacol Res 2021;164:105384.","journal-title":"Pharmacol Res"},{"key":"3809_CR21","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s11655-022-3574-z","volume":"28","author":"Y Yang","year":"2022","unstructured":"Yang Y, Ge FL, Zhan XY, Mu WQ, Li ZY, Lin L, et al. Schisandra chinensis oil attenuates aristolochic acid I-induced nephrotoxicity in vivo and in vitro. Chin J Integr Med 2022;28:603\u2013611.","journal-title":"Chin J Integr Med"},{"key":"3809_CR22","first-page":"88","volume-title":"Pharmacological experiment methodology","author":"H Gao","year":"2012","unstructured":"Gao H, ed. Pharmacological experiment methodology. Beijing: China Medical Science and Technology Press; 2012:88\u201389."},{"key":"3809_CR23","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1021\/tx3000889","volume":"25","author":"BH Yun","year":"2012","unstructured":"Yun BH, Rosenquist TA, Sidorenko V, Iden CR, Chen CH, Pu YS, et al. Biomonitoring of aristolactam-DNA adducts in human tissues using ultra-performance liquid chromatography\/ion-trap mass spectrometry. Chem Res Toxicol 2012;25:1119\u20131131.","journal-title":"Chem Res Toxicol"},{"key":"3809_CR24","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1002\/hep.30863","volume":"71","author":"ZN Lu","year":"2020","unstructured":"Lu ZN, Luo Q, Zhao LN, Shi Y, Wang N, Wang L, et al. The mutational features of aristolochic acid-induced mouse and human liver cancers. Hepatology 2020;71:929\u2013942.","journal-title":"Hepatology"},{"key":"3809_CR25","series-title":"dissertation","volume-title":"Analysis of aristolochic acid-DNA adducts in rats treated with Guanmutong","author":"L Yi","year":"2014","unstructured":"Yi L. Analysis of aristolochic acid-DNA adducts in rats treated with Guanmutong [dissertation]. Beijing: Peking University; 2014."},{"key":"3809_CR26","first-page":"2634","volume":"45","author":"J Yang","year":"2020","unstructured":"Yang J, Jia Z, Liu J, Li Y, Li Q, Su R, et al. HPLC\u2013MS\/MS determination of aristolochic acid-DNA adducts in the mouse liver and kidney. China J Chin Mater Med (Chin) 2020;45:2634\u20132641.","journal-title":"China J Chin Mater Med (Chin)"},{"key":"3809_CR27","first-page":"470","volume":"14","author":"ZE Fang","year":"2022","unstructured":"Fang ZE, Guo Y, Wang Z, He T, Wang J, Bai Z, et al. Asari Radix et Rhizoma consumption lacks relevance for hepatocellular carcinoma in patients: a retrospective cohort study. Chin Herb Med 2022;14:470\u2013475.","journal-title":"Chin Herb Med"},{"key":"3809_CR28","first-page":"17","volume":"11","author":"A Liang","year":"2017","unstructured":"Liang A, Gao Y, Zhang B. Safety issues and countermeasures of Chinese medicines containing aristolochic acid. China Food Drug Administr (Chin) 2017;11:17\u201320.","journal-title":"China Food Drug Administr (Chin)"},{"key":"3809_CR29","first-page":"553","volume":"20","author":"L Nie","year":"2023","unstructured":"Nie L, Wang X, Li J, Dai Z, Kang S, Ma S. Analysis and preliminary risk assessment of aristolochic acid in Chinese herbal medicines (drinking tablets). Pharmacovigilance China 2023;20:553\u2013559.","journal-title":"Pharmacovigilance China"},{"key":"3809_CR30","doi-asserted-by":"publisher","first-page":"105349","DOI":"10.1016\/j.tiv.2022.105349","volume":"81","author":"M Qu","year":"2022","unstructured":"Qu M, Xu H, Chen J, Xu B, Li Z, Ma B, et al. Differential comparison of genotoxic effects of aristolochic acid I and II in human cells by the mass spectroscopic quantification of \u03b3 -H2AX. Toxicol In Vitro 2022;81:105349.","journal-title":"Toxicol In Vitro"},{"key":"3809_CR31","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s11655-023-3560-0","volume":"30","author":"T Su","year":"2024","unstructured":"Su T, Fang ZE, Guo Y, Wang C, Wang J, Ji D, et al. No incidence of liver cancer was observed in a retrospective study of patients with aristolochic acid nephropathy. Chin J Integr Med 2024;30:99\u2013106.","journal-title":"Chin J Integr Med"},{"key":"3809_CR32","doi-asserted-by":"publisher","first-page":"104234","DOI":"10.1016\/j.phrs.2019.04.018","volume":"154","author":"A Jetter","year":"2020","unstructured":"Jetter A, Kullak-Ublick GA. Drugs and hepatic transporters: a review. Pharmacol Res 2020;154:104234.","journal-title":"Pharmacol Res"},{"key":"3809_CR33","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1016\/j.etap.2013.07.017","volume":"36","author":"C Feng","year":"2013","unstructured":"Feng C, Xie X, Wu M, Li C, Gao M, Liu M, et al. Tanshinone I protects mice from aristolochic acid I-induced kidney injury by induction of CYP1A. Environ Toxicol Pharmacol 2013;36:850\u2013857.","journal-title":"Environ Toxicol Pharmacol"},{"key":"3809_CR34","doi-asserted-by":"publisher","first-page":"16454","DOI":"10.3390\/ijms160716454","volume":"16","author":"K Wang","year":"2015","unstructured":"Wang K, Feng C, Li C, Yao J, Xie X, Gong L, et al. Baicalin protects mice from aristolochic acid I-induced kidney injury by induction of CYP1A through the aromatic hydrocarbon receptor. Int J Mol Sci 2015;16:16454\u201316468.","journal-title":"Int J Mol Sci"},{"key":"3809_CR35","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1038\/s41401-023-01052-3","volume":"44","author":"YP Dong","year":"2023","unstructured":"Dong YP, Chen SZ, He HS, Sun ZR, Jiang LX, Gu YQ, et al. Skullcapflavone II, a novel NQO1 inhibitor, alleviates aristolochic acid I-induced liver and kidney injury in mice. Acta Pharmacol Sin 2023;44:1429\u20131441.","journal-title":"Acta Pharmacol Sin"},{"key":"3809_CR36","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1038\/ki.2012.264","volume":"82","author":"TER Baudoux","year":"2012","unstructured":"Baudoux TER, Pozdzik AA, Arlt VM, De Prez EG, Antoine MH, Quellard N, et al. Probenecid prevents acute tubular necrosis in a mouse model of aristolochic acid nephropathy. Kidney Int 2012;82:1105\u20131113.","journal-title":"Kidney Int"},{"key":"3809_CR37","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1093\/toxsci\/kfaa033","volume":"175","author":"C Li","year":"2020","unstructured":"Li C, Wang X, Bi Y, Yu H, Wei J, Zhang Yi, et al. Potent inhibitors of organic anion transporters 1 and 3 from natural compounds and their protective effect on aristolochic acid nephropathy. Toxicol Sci 2020;175:279\u2013291.","journal-title":"Toxicol Sci"}],"container-title":["Chinese Journal of Integrative Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11655-024-3809-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11655-024-3809-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11655-024-3809-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,25]],"date-time":"2025-01-25T02:01:08Z","timestamp":1737770468000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11655-024-3809-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,8]]},"references-count":37,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["3809"],"URL":"https:\/\/doi.org\/10.1007\/s11655-024-3809-2","relation":{},"ISSN":["1672-0415","1993-0402"],"issn-type":[{"type":"print","value":"1672-0415"},{"type":"electronic","value":"1993-0402"}],"subject":[],"published":{"date-parts":[[2024,6,8]]},"assertion":[{"value":"23 February 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflicts of interest. During the preparation of this work, we used [BioRender] to construct Figures 1 and 2A. Publication and licencing rights were obtained. The authors take full responsibility for the contents of this study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}